Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Lars Sorensen's plans to build Novo Nordisk ($NVO) into one of the world's biggest drugmakers got a big boost with the news that the European Commission has approved Tresiba, its long-acting insulin, which will now be positioned as a rival to Sanofi's ($SNY) megablockbuster Lantus. Novo also gained approval in Europe for the insulin Ryzodeg.
Novo plans to roll out Tresiba (insulin degludec) in the U.K. and Denmark in the first half of 2013 while prepping for a launch in the rest of Europe in the second half. Ryzodeg will follow Tresiba's launch in about a year. Tresiba is under regulatory review at the FDA after winning an advisory committee vote supporting its approval in the U.S.
http://www.fiercebiotech.com/story/...-blockbuster-diabetes-drug-hopeful/2013-01-22
Novo plans to roll out Tresiba (insulin degludec) in the U.K. and Denmark in the first half of 2013 while prepping for a launch in the rest of Europe in the second half. Ryzodeg will follow Tresiba's launch in about a year. Tresiba is under regulatory review at the FDA after winning an advisory committee vote supporting its approval in the U.S.
http://www.fiercebiotech.com/story/...-blockbuster-diabetes-drug-hopeful/2013-01-22